EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug ...

Surmodics has revealed that it is still recovering after it was hit by a cyberattack in June 2025. In a Form 8-K filed with the US Securities and Exchange Commission (SEC), the maker of the Pounce XL ...

Shares of SurModics (SRDX) have been on an upswing since reporting a solid fiscal third quarter in early August, and recently hit its 52-week high of $22.21 on October 5. With a year-to-date return of ...

Surmodics makes coatings for medical devices and manufactures chemicals for diagnostic immunoassay tests. On Wednesday morning, before the markets opened, the healthcare company announced that the FDA ...

Surmodics (NASDAQ:SRDX) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement. Analysts estimate that Surmodics will ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today certain ...

As proxy fights go, the battle for SurModics Inc. (NASDAQ:SRDX), based in Eden Prairie, is downright tame — for now. Last week, Ramius LLC, the alternative investment firm of Cowen & Co. that recently ...

SurModics (SRDX) is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics.

You certainly can’t accuse Bruce Barclay of standing still. Since SurModics Inc. (NASDAQ: SRDX) named Barclay CEO in 2005, Barclay has reorganized the drug company’s business units, purchased land, ...

Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than the market estimate and sales beat the same by 8.3%. The strong ...